RxDoctor Payments Data

Monika Kaul, MD

Family Medicine · Bridgeport, CTNPI 1154569200

Payments from drug & device makers

$984in general payments, 2019–2025

Across 29 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$513
  • Johnson & Johnson$128
  • AbbVie$74
  • Novo Nordisk$43
  • Amgen$43
  • Pfizer$42
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$96998%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$984 in reported general payments places this provider in the 70th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$36,864
Medicare patients
151
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$96,825
EliquisApixaban50$68,946
FarxigaDapagliflozin Propanediol42$66,808
JanuviaSitagliptin Phosphate42$59,034
JardianceEmpagliflozin43$55,911
XareltoRivaroxaban19$27,531
LinzessLinaclotide19$20,505
TrulicityDulaglutide12$19,401
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$18,111
Breo ElliptaFluticasone/Vilanterol13$9,101
SymbicortBudesonide/Formoterol Fumarate17$4,904
Rosuvastatin Calcium285$3,410
SynthroidLevothyroxine Sodium24$2,270
Levothyroxine Sodium177$2,025
Omega-3 Acid Ethyl Esters13$1,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$43$96,82551 claims
AstraZenecaFarxiga, Symbicort$513$71,71259 claims
PfizerEliquis$42$68,94650 claims
MerckJanuvia$30$59,03442 claims
Boehringer IngelheimJardiance$18$55,91143 claims
Johnson & JohnsonXarelto$128$27,53119 claims
AbbVieLinzess, Synthroid$74$22,77543 claims
Lilly USA, LLCTrulicity$28$19,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →